UnitedHealth Group Inc. — 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012; filed February 6, 2013. This is an annual report, not a standalone fourth-quarter filing. UnitedHealth Group operates health benefits businesses under UnitedHealthcare and health services businesses under Optum.
Financial performance
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Revenue | $110.6 billion | $101.9 billion | +9% |
| Earnings from operations | $9.25 billion | $8.46 billion | +9% |
| Net earnings | $5.53 billion | $5.14 billion | +7% |
| Diluted EPS | $5.28 | $4.73 | +12% |
| Operating margin | 8.4% | 8.3% | +0.1 percentage point |
| Medical care ratio | 80.4% | 80.8% | −0.4 percentage point |
| Operating cash flow | $7.16 billion | $6.97 billion | +3% |
Medical costs were $80.23 billion, up 8%; operating costs were $17.31 billion, up 11%. Net margin was 5.0%. Favorable development of prior-year medical cost reserves contributed $860 million to 2012 results, versus $720 million in 2011.
Fourth quarter: Revenue was $28.77 billion, operating earnings $2.10 billion, net earnings $1.24 billion, and diluted EPS $1.20. In Q4 2011, these were $25.92 billion, $2.07 billion, $1.26 billion, and $1.17, respectively.
Segments and material changes
- UnitedHealthcare: Revenue increased 8% to $103.42 billion and operating earnings rose 8% to $7.82 billion. Total medical enrollment increased by 6.4 million, including 4.4 million people added through the Amil acquisition. Commercial risk-based membership declined 2%, while commercial fee-based membership grew 8%.
- Optum: Combined segment revenue increased 3% to $29.39 billion and operating earnings increased 14% to $1.44 billion. OptumInsight operating earnings rose 27%; OptumRx revenue declined 5% and operating earnings fell 14%, mainly reflecting lower Medicare Part D prescription volumes and growth investments.
- Standalone Medicare Part D membership declined by 630,000; the company attributed much of the reduction to losing about 470,000 auto-assigned low-income members after bids exceeded government pricing thresholds.
- UnitedHealth Group acquired approximately 65% of Brazil-based Amil in 2012 for approximately $3.5 billion. The acquisition added $7.36 billion of goodwill; the company planned a tender offer for a further 25% in the first half of 2013. Purchase price allocation remained subject to adjustment.
Financial position, liquidity and capital returns
- At year-end, total assets were $80.89 billion, shareholders’ equity $31.18 billion, and cash and cash equivalents $8.41 billion. Cash and investments were reported at $29.15 billion in selected financial data; the filing also presents $28.3 billion of cash, cash equivalents and available-for-sale investments, excluding certain classifications.
- Commercial paper and long-term debt totaled $16.75 billion, up from $11.64 billion. The debt-to-debt-plus-equity ratio increased to 35.0% from 29.1%; the company was within its 50% covenant limit. It had $4.0 billion of revolving credit facilities available, with none drawn.
- Operating cash flow was $7.16 billion; investing cash outflow was $8.65 billion, including $6.28 billion of net acquisition payments. Financing cash flow was $471 million.
- The company repurchased 57 million shares for $3.1 billion and paid $820 million in dividends. The annual dividend rate was increased to $0.85 per share in June 2012.
Outlook, commentary and risks
- No consolidated numerical earnings or revenue guidance for 2013 is provided in the text. Management anticipated highly competitive commercial pricing, continued pressure on commercial risk-based membership, and pressure on Medicare and Medicaid margins from government rates. It expected 2013 medical cost trend to increase slightly from 2012’s level, which was under 5.5% for commercial business.
- Management expected OptumRx to bring approximately 12 million UnitedHealthcare commercial members onto its platform during 2013. The TRICARE West contract was expected to begin operations April 1, 2013; the base administrative services contract was expected to generate $1.4 billion over five years.
- Management highlighted the uncertain effects of health reform, including 2014 insurance-industry assessments, reinsurance fees, exchange-market changes, medical loss ratio rules and limits on premium increases. Medicare Advantage benchmark reductions and the potential effects of federal sequestration were also noted.
- Key operating risks include medical-cost estimation and utilization, provider pricing, government program funding and contract renewals, regulatory audits and risk-adjustment data reviews, privacy and cybersecurity, competition, and integration and foreign-exchange exposure associated with Amil.
- Contingency: California regulators were seeking approximately $325 million in penalties over claims-processing matters. The company disputed the allegations and said it could not reasonably estimate a loss range. Out-of-network reimbursement litigation and government reviews, including Medicare risk-adjustment audits, were also disclosed.
Important facts for investors to verify
- Whether earnings growth remains solid after accounting for $860 million of favorable prior-period reserve development.
- How the Amil tender offer, final purchase accounting, integration and Brazilian real exposure affect debt, cash flow and returns.
- Progress and operating performance in the OptumRx transition for approximately 12 million members.
- Actual effects of 2013–2014 health reform costs, government reimbursement changes, exchange participation and rate approvals on margins and enrollment.
- Updates to the California penalty proceeding, Medicare risk-adjustment audits and other disclosed litigation or investigations.
- The filing reports unqualified audit opinions on the consolidated financial statements and internal controls; the internal-control assessment excluded Amil, which represented 10% of consolidated assets and 1% of 2012 revenue.